Melanoma brain metastasis: Overview of current management and emerging targeted therapies

Expert Review of Neurotherapeutics

Volumn 12, Issue 10, 2012, Pages 1207-1215

  Fonkem, Ekokobe ^a,c   Uhlmann, Erik J ^a   Floyd, Scott R ^a   Mahadevan, Anand ^a   Kasper, Ekkehard ^a   Eton, Omar ^b   Wong, Eric T ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

Author keywords

brain metastasis; immunotherapy; melanoma; targeted therapy

Indexed keywords

DABRAFENIB; DACARBAZINE; IPILIMUMAB; TEMOZOLOMIDE; THALIDOMIDE; VEMURAFENIB;

ARTHRALGIA; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; COUGHING; DOSE RESPONSE; DRUG EFFICACY; FACIAL NERVE PARALYSIS; FATIGUE; GENE MUTATION; HERPES ZOSTER; HERPETIC STOMATITIS; HUMAN; HYPERTRANSAMINASEMIA; MACULOPAPULAR RASH; MELANOMA; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MUSCLE SPASM; NAUSEA; OVERALL SURVIVAL; PERIPHERAL EDEMA; REVIEW; SINUSITIS; STEREOTACTIC RADIOSURGERY; UNSPECIFIED SIDE EFFECT; VOMITING;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNITY, CELLULAR; INDOLES; MELANOMA; MOLECULAR TARGETED THERAPY; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; SIGNAL TRANSDUCTION; SULFONAMIDES;

EID: 84867772278     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.111     Document Type: Review

References (75)

1. Lens MB, Dawes M. Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma. Br. J. Dermatol. 150(2), 179-185 (2004).
2. Sampson JH, Carter JH Jr, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J. Neurosurg. 88(1), 11-20 (1998).
3. Madajewicz S, Karakousis C, West CR, Caracandas J, Avellanosa AM. Malignant melanoma brain metastases. Review of Roswell Park Memorial Institute experience. Cancer 53(11), 2550-2552 (1984).
4. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61(5), 759-767 (1990).
5. Gray-Schopfer VC, da Rocha Dias S, Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev. 24(1), 165-183 (2005).
6. Monzon J, Liu L, Brill H et al. CDKN2A mutations in multiple primary melanomas. N. Engl. J. Med. 338(13), 879-887 (1998).
7. Chapman PB, Hauschild A, Robert C et al.; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364(26), 2507-2516 (2011).
8. Flaherty KT, Puzanov I, Kim KB et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363(9), 809-819 (2010).
9. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011).
10. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 22(14), 2865-2872 (2004).
11. Schouten LJ, Rutten J, Huveneers HA, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 94(10), 2698-2705 (2002).
12. Amer MH, Al-Sarraf M, Baker LH, Vaitkevicius VK. Malignant melanoma and central nervous system metastases: Incidence, diagnosis, treatment and survival. Cancer 42(2), 660-668 (1978).
13. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am. J. Surg. 135(6), 807-810 (1978).
14. Bedikian AY, Wei C, Detry M et al. Predictive factors for the development of brain metastasis in advanced unresectable metastatic melanoma. Am. J. Clin. Oncol. 34(6), 603-610 (2011).
15. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med. 1(2), 149-153 (1995).
16. Gleissner B, Chamberlain MC. Neoplastic meningitis. Lancet Neurol. 5(5), 443-452 (2006).
17. Kyritsis AP, Markoula S, Levin VA. A systematic approach to the management of patients with brain metastases of known or unknown primary site. Cancer Chemother. Pharmacol. 69(1), 1-13 (2012).
18. McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN. Treatment of brain metastases from melanoma. Mayo Clin. Proc. 78(12), 1529-1536 (2003).
19. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: A literature review. Cancer Control 16(3), 248-255 (2009).
20. Patchell RA, Tibbs PA, Regine WF et al. Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280(17), 1485-1489 (1998).
21. Patchell RA, Tibbs PA, Walsh JW et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322(8), 494-500 (1990).
22. Raizer JJ, Hwu WJ, Panageas KS et al. Brain and leptomeningeal metastases from cutaneous melanoma: Survival outcomes based on clinical features. Neuro-oncology 10(2), 199-207 (2008).
23. Fertil B, Malaise EP. Inherent cellular radiosensitivity as a basic concept for human tumor radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 7(5), 621-629 (1981).
24. Fertil B, Malaise EP. Intrinsic radiosensitivity of human cell lines is correlated with radioresponsiveness of human tumors: Analysis of 101 published survival curves. Int. J. Radiat. Oncol. Biol. Phys. 11(9), 1699-1707 (1985).
25. Nieder C, Marienhagen K, Geinitz H, Grosu AL. Can current prognostic scores reliably guide treatment decisions in patients with brain metastases from malignant melanoma? J. Cancer Res. Ther. 7(1), 47-51 (2011).
26. Rate WR, Solin LJ, Turrisi AT. Palliative radiotherapy for metastatic malignant melanoma: Brain metastases, bone metastases, and spinal cord compression. Int. J. Radiat. Oncol. Biol. Phys. 15(4), 859-864 (1988).
27. Smalley SR, Schray MF, Laws ER Jr, O'Fallon Jr. Adjuvant radiation therapy after surgical resection of solitary brain metastasis: Association with pattern of failure and survival. Int. J. Radiat. Oncol. Biol. Phys. 13(11), 1611-1616 (1987).
28. Atkins MB, Sosman JA, Agarwala S et al. Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: A Phase II Cytokine Working Group study. Cancer 113(8), 2139-2145 (2008).
29. Margolin K, Atkins B, Thompson A et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: A Phase II trial of the Cytokine Working Group. J. Cancer Res. Clin. Oncol. 128(4), 214-218 (2002).
30. Sause WT, Cooper JS, Rush S et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int. J. Radiat. Oncol. Biol. Phys. 20(3), 429-432 (1991).
31. Sperduto PW, Kased N, Roberge D et al. Summary report on the graded prognostic assessment: An accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J. Clin. Oncol. 30(4), 419-425 (2012).
32. Phillips MH, Stelzer KJ, Griffin TW, Mayberg MR, Winn HR. Stereotactic radiosurgery: A review and comparison of methods. J. Clin. Oncol. 12(5), 1085-1099 (1994).
33. Selek U, Chang EL, Hassenbusch SJ 3rd et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int. J. Radiat. Oncol. Biol. Phys. 59(4), 1097-1106 (2004).
34. Powell JW, Chung CT, Shah HR et al. Gamma knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma. J. Neurosurg. 109(Suppl.), 122-128 (2008).
35. Andrews DW, Scott CB, Sperduto PW et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: Phase III results of the RTOG 9508 randomised trial. Lancet 363(9422), 1665-1672 (2004).
36. Sperduto PW, Chao ST, Sneed PK et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: A multi-institutional analysis of 4,259 patients. Int. J. Radiat. Oncol. Biol. Phys. 77(3), 655-661 (2010).
37. Agarwala SS, Kirkwood JM, Gore M et al. Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A Phase II study. J. Clin. Oncol. 22(11), 2101-2107 (2004).
38. Boogerd W, de Gast GC, Dalesio O. Temozolomide in advanced malignant melanoma with small brain metastases: Can we withhold cranial irradiation? Cancer 109(2), 306-312 (2007).
39. Antonadou D, Paraskevaidis M, Sarris G et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J. Clin. Oncol. 20(17), 3644-3650 (2002).
40. Hofmann M, Kiecker F, Wurm R et al. Temozolomide with or without radiotherapy in melanoma with unresectable brain metastases. J. Neurooncol. 76(1), 59-64 (2006).
41. Hwu WJ, Lis E, Menell JH et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma: A Phase II study. Cancer 103(12), 2590-2597 (2005).
42. Amaravadi RK, Schuchter LM, McDermott DF et al. Phase II trial of temozolomide and sorafenib in advanced melanoma patients with or without brain metastases. Clin. Cancer Res. 15(24), 7711-7718 (2009).
43. Jacquillat C, Khayat D, Banzet P et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother. Pharmacol. 25(4), 263-266 (1990).
44. Einzig AI, Hochster H, Wiernik PH et al. A Phase II study of taxol in patients with malignant melanoma. Invest. New Drugs 9(1), 59-64 (1991).
45. Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3(7), 611-618 (2002).
46. Weber JS, O'Day S, Urba W et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J. Clin. Oncol. 26(36), 5950-5956 (2008).
47. Wolchok JD, Weber JS, Hamid O et al. Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials. Cancer Immun. 10, 9 (2010).
48. Hodi FS, O'Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010).
49. Robert C, Thomas L, Bondarenko I et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N. Engl. J. Med. 364(26), 2517-2526 (2011).
50. Hodi FS, Oble DA, Drappatz J et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat. Clin. Pract. Oncol. 5(9), 557-561 (2008).
51. Downey SG, Klapper JA, Smith FO et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin. Cancer Res. 13(22 Pt 1), 6681-6688 (2007).
52. Schartz NE, Farges C, Madelaine I et al. Complete regression of a previously untreated melanoma brain metastasis with ipilimumab. Melanoma Res. 20(3), 247-250 (2010).
53. Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: Patient cases. Cancer Immun. 8, 1 (2008).
54. Lawrence DP, Hamid HO, Mcdermott DF et al. Phase II trial of ipilimumab monotherapy in melanoma patients with brain metastases. J. Clin. Oncol. 28(15 Suppl.), Abstract 8523 (2010).
55. Cantrell D. Protein kinase B (Akt) regulation and function in T lymphocytes. Semin. Immunol. 14(1), 19-26 (2002).
56. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192(7), 1027-1034 (2000).
57. Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 99(19), 12293-12297 (2002).
58. Brahmer JR, Drake CG, Wollner I et al. Phase I study of single-agent antiprogrammed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28(19), 3167-3175 (2010).
59. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
60. Berger R, Rotem-Yehudar R, Slama G et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14(10), 3044-3051 (2008).
61. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J. Clin. Oncol. 29(36), 4828-4836 (2011).
62. Sznol M, Hodi FS, Margolin K. Phase I study of BMS-663513, a fully human anti-CD137 against monoclonal antibody, in patients (pts) with advanced cancer. J. Clin. Oncol. 2008(26), Abstract 3007 (2008).
63. Gough MJ, Weinberg AD. OX40 (CD134) and OX40L. Adv. Exp. Med. Biol. 647, 94-107 (2009).
64. Sznol M. Betting on immunotherapy for melanoma. Curr. Oncol. Rep. 11(5), 397-404 (2009).
65. Triebel F. LAG-3: A regulator of T-cell and DC responses and its use in therapeutic vaccination. Trends Immunol. 24(12), 619-622 (2003).
66. Grosso JF, Kelleher CC, Harris TJ et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 117(11), 3383-3392 (2007).
67. Buckmelter AJ, Ren L, Laird ER et al. The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors. Bioorg. Med. Chem. Lett. 21(4), 1248-1252 (2011).
68. Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem. J. 351(Pt 2), 289-305 (2000).
69. Flaherty KT, Yasothan U, Kirkpatrick P. Vemurafenib. Nat. Rev. Drug Discov. 10(11), 811-812 (2011).
70. Dummer R, Rinderknecht J, Goldinger SM et al. An open-label pilot study of vermurafenib in previously treated metastatic melanoma patients with brain metastases. J. Clin. Oncol. 29(15 Suppl.), Abstract 8548 (2011).
71. Rochet NM, Kottschade LA, Markovic SN. Vemurafenib for melanoma metastases to the brain. N. Engl. J. Med. 365(25), 2439-2441 (2011).
72. Falchook GS, Long GV, Kurzrock R et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A Phase 1 dose-escalation trial. Lancet 379(9829), 1893-1901 (2012).
73. Kefford RF, Arkenau H, Brown MP. Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other soild tumors. J. Clin. Oncol. 28(15 Suppl.), Abstract 8503 (2010).
74. Alcalá AM, Flaherty KT. BRAF inhibitors for the treatment of metastatic melanoma: Clinical trials and mechanisms of resistance. Clin. Cancer Res. 18(1), 33-39 (2012).
75. Schwartz GK, Robertson S, Shen A. A Phase I study of XL281, a selective oral RAF kinase inhibitor, in patients (pts) with advanced solid tumors. J. Clin. Oncol. 27(15 Suppl.), Abstract 3513 (2009).